Neuros Medical’s ALTIUS Receives Medicare Pass-Through Status

Neuros Medical announced the reimbursement decision on November 5, 2026 that the Centers for Medicare & Medicaid Services has finalized Medicare transitional pass-through status for its ALTIUS Direct Electrical Nerve Stimulation System. Beginning January 1, 2027, the decision establishes separate incremental reimbursement when the system is implanted in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs).

The product-specific decision is part of the calendar-year 2027 hospital outpatient and ASC payment rule, which CMS issued on November 4, 2026. A newly assigned Category C-code provides separate device reimbursement above the standard Ambulatory Payment Classification procedural payment rate. The announcement does not identify the specific code or disclose a dollar payment rate.

Payment Targets Facility Acquisition Costs

Neuros said standard bundled Medicare payments often leave a significant financial gap for facilities purchasing high-cost neurostimulation implants. Under the new policy, separate pass-through payment can be made to HOPDs and ASCs for ALTIUS’s acquisition cost. That changes the reimbursement framework around an already-approved device rather than expanding what the implant is authorized to treat.

President and CEO David Veino tied the decision to facility adoption: “Historically, technology acquisition costs presented a significant hurdle for outpatient facilities and ASCs, limiting access despite strong patient and provider demand.” He said the status would allow Medicare lower limb amputee patients to access the therapy in the most appropriate care setting while enabling hospital and ASC partners to cover their technology costs.

ALTIUS pass-through payment will remain in effect for up to three years. The final rule describes this mechanism as temporary additional payment lasting at least two but not more than three years.

In the same rulemaking, CMS approved nine device pass-through applications, including ALTIUS, and denied four. The agency received 19 complete applications and sought comment on 13 after six applicants withdrew.

From FDA Approval to Medicare Payment

Neuros announced U.S. Food and Drug Administration approval for ALTIUS on August 28, 2024. The CMS decision is therefore a later commercial-access milestone, not the system’s initial regulatory authorization. ALTIUS is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees.

The system consists of a nerve cuff electrode placed around an affected nerve and an implantable pulse generator. Patients initiate an on-demand 30-minute treatment session as needed. Neuros says the technology is designed to inhibit pain-signal transmission from damaged peripheral nerves near the amputation site to the central nervous system.

Neuros’s Market Access and Reimbursement team will provide coding, billing and health-economics support to clinicians, ASC managers and hospital administrators. That support points to the immediate commercial task: converting a product-specific payment decision into coding and billing processes that outpatient providers can use when separate reimbursement begins.